| Literature DB >> 24719548 |
Mahavir Chhajed1, Anil Kumar Shrivastava2, Vijay Taile3.
Abstract
ABSTRACT: A series of imines 5-amino-1,3,4-thiadiazol-2-[(N-substituted benzyol)]sulphonamide derivatives were synthesized from various aromatic aldehydes and substituted with benzoyl acetazolamides under different reaction conditions and were evaluated for their antioxidant and free radical scavenging, antimitotic activity by Allium cepa meristem root model and cytotoxicity activity against HEK 293 (human epidermal kidney cell line), BT474 (breast cancer cell line) and NCI-H226 (lung cancer cell line) by MTT assay. Some of the synthesized compounds showed moderately potent cytotoxicity compared to indisulam. GRAPHICAL ABSTRACT: A series of imines 5-amino-1,3,4-thiadiazol-2-[(N-substituted benzyol)]sulphonamide derivatives (9a-j); 5-amino-1,3,4-thiadiazol-2-[N-(substituted benzoyl)]sulphonamide (4a-g); 5-(4-acetamido phenyl sulphonamido)-1,3,4-thiadiazol-2-[N-(substituted benzoyl)]sulphonamide (6a-g); and 5-(4-amino phenyl sulphonamido)-1,3,4-thiadiazol-2-[N-(substituted benzoyl)]sulphonamide (7a-g) were synthesized from acetazolamide and were investigated for the in vitro anticancer by MTT assay, free radical scavenging and antimitotic activity by Allium cepa root meristem model. Experimental observations indicate that synthesized compounds were moderately potent anticancer agents.Entities:
Keywords: 1,3,4-Thiadiazole; Antimitotic; Antioxidants; Cytotoxicity; MTT assay
Year: 2013 PMID: 24719548 PMCID: PMC3973950 DOI: 10.1007/s00044-013-0890-z
Source DB: PubMed Journal: Med Chem Res ISSN: 1054-2523 Impact factor: 1.965
Scheme 1Synthesis of 5-amino-1,3,4-thiadiazol-2-[N-(substituted benzoyl)]sulphonamide (4a–g), 5-(4-acetamido phenyl sulphonamido)-1,3,4-thiadiazole-2-[N-(substituted benzoyl)]sulphonamide (6a–g), 5-(4-amino phenyl sulphonamido)-1,3,4-thiadiazole-2-[N-(substituted benzoyl)]sulphonamide (7a–g), and 5-arylidine amino-1,3,4-thiadiazol-2-[N-(substituted benzoyl)]sulphonamide (9a–j)
Comparative IC50 inhibitory concentration of synthesized compounds and standards against different free radicals
| Compound no. | IC50 inhibitory concentration (nM/mL)a | ||||
|---|---|---|---|---|---|
| ABTS+ radicalb | Lipid peroxidationc | DPPH radicald | Superoxide anione | Nitric oxide radicalf | |
|
| 73.30 ± 7.05* [4.07] | 121.63 ± 18.60 [10.74] | 134.07 ± 12.90* [22.34] | 151.89 ± 14.42* [24.97] | 103.67 ± 7.50* [12.99] |
|
| 93.30 ± 10.67* [6.16] | 133.02 ± 11.53* [6.65] | 88.19 ± 11.09* [6.40] | 76.31 ± 11.80* [6.81] | 52.57 ± 16.73* [9.66] |
|
| 196.17 ± 16.60* [9.58] | 101.78 ± 14.51** [8.38] | 41.27 ± 4.23** [2.44] | 128.09 ± 21.74* [12.55] | 81.90 ± 10.44* [6.02] |
|
| 55.61 ± 6.98* [4.03] | 164.49 ± 14.56* [8.41] | 63.56 ± 8.35** [4.82] | 74.52 ± 8.3* [4.79] | 53.03 ± 6.74* [3.89] |
|
| 47.89 ± 9.90* [5.72] | 134.34 ± 14.70** [8.49] | 107.28 ± 18.13** [10.46] | 135.52 ± 22.55* [13.02] | 155.21 ± 17.64* [10.19] |
|
| 207.14 ± 17.41* [10.05] | 203.74 ± 20.11** [11.61] | 80.63 ± 11.38** [6.57] | 36.6604 ± 14.39* [8.31] | 38.00 ± 11.77* [6.79] |
| Std | 84.54 ± 9.39* [5.42] | 150.12 ± 16.93** [9.77] | 187.20 ± 35.38* [19.96] | 171.36 ± 9.10** [5.25] | 73.67 ± 9.44* [5.45] |
* P < 0.05; ** P < 0.01
aIC50 value reported as Conc. ± SD [SEM]; SEM of three independent experiments performed in duplicate
bStandard used was trolox
cStandard used was ascorbic acid
dStandard used was ascorbic acid
eStandard used was catechin
fStandard used was curcumin
Mitotic index and chromosome and mitotic aberrations in the root meristem cells of Allium cepa after the synthesized compounds treatment
| Treatment groups | Dose | MI (%) ± SEMa,b | Chromosome breaks (%) ± SEMb | Stickiness (%) ± SEMb | Polar deviations (%) ± SEMb | Aberrant cells (%) ± SEMb | MNC (‰) ± SEMb |
|---|---|---|---|---|---|---|---|
| NCc | – | 6.22 ± 0.32 | – | 0.92 ± 0.32 | 6.89 ± 1.32 | 10.12 ± 1.58 | 0.35 ± 0.12 |
| PCd | 2 × 10−2 M | 1.86 ± 0.23 | – | 36.31 ± 9.84 | 12.36 ± 3.36 | 43.20 ± 7.10 | 0.59 ± 0.09 |
|
| 1 mg/mL | 3.22 ± 0.16 | 6.22 ± 1.02 | 6.64 ± 2.38 | 8.62 ± 2.16 | 19.28 ± 5.22 | 0.34 ± 0.15 |
|
| 1 mg/mL | 2.77 ± 0.19 | 3.36 ± 0.57 | 9.12 ± 1.33 | 7.32 ± 1.24 | 24.64 ± 7.01 | 0.42 ± 0.18 |
|
| 1 mg/mL | 0.53 ± 0.03 | – | 28.04 ± 6.34 | 7.22 ± 2.61 | 38.54 ± 8.18 | 0.36 ± 0.14 |
|
| 1 mg/mL | 2.34 ± 0.19 | 0.96 ± 0.46 | 14.48 ± 2.52 | 9.15 ± 6.92 | 25.33 ± 9.42 | 0.51 ± 0.17 |
|
| 1 mg/mL | 1.27 ± 0.11 | 2.72 ± 0.94 | 9.88 ± 1.46 | 8.41 ± 1.35 | 26.74 ± 6.56 | 0.21 ± 0.06 |
|
| 1 mg/mL | 0.91 ± 0.13 | 1.47 ± 0.13 | 21.96 ± 7.22 | 7.33 ± 2.52 | 33.41 ± 9.47 | 0.39 ± 0.20 |
|
| 1 mg/mL | 0.41 ± 0.04 | – | 32.24 ± 6.92 | 10.26 ± 2.13 | 40.48 ± 12.94 | 0.48 ± 0.32 |
|
| 1 mg/mL | 1.07 ± 0.13 | 2.43 ± 0.67 | 16.50 ± 3.23 | 8.91 ± 1.56 | 29.83 ± 5.03 | 0.31 ± 0.14 |
|
| 1 mg/mL | 3.07 ± 0.22 | 7.33 ± 2.06 | 7.35 ± 2.06 | 6.57 ± 1.33 | 22.41 ± 6.18 | 0.61 ± 0.15 |
aThe MI values indicates that lower the MI value higher the activity
bAll the values are expressed as mean ± SEM “data are the mean, SEM of 3 independent experiments performed in duplicate”
cDistilled water was used as negative control (NC)
dEthyl methanesulphonate (EMS) was used as positive control (PC)
Anticancer activity (% cytotoxicity) and CTC50 values of synthesized compounds on HEK 293 (human epidermal kidney cell line)
| Treatment | % cytotoxicity (100 − % cell survival) of HEK 293 cell line at conc. (μM) | CTCC50 (μM)a | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 100 | 33.33 | 11.11 | 3.7 | 1.23 | 0.41 | 0.13 | 0.045 | 0.015 | 0.005 | ||
| Log conc. | |||||||||||
| 2.00 | 1.52 | 1.05 | 0.57 | 0.09 | −0.39 | −0.89 | −1.35 | −1.82 | −2.30 | ||
|
| 32.96 | 31.71 | 29.48 | 28.87 | 28.54 | 28.18 | 26.93 | 26.64 | 25.82 | 25.57 | 64.363 |
|
| 65.41 | 63.14 | 62.32 | 59.72 | 58.13 | 57.56 | 53.61 | 50.42 | 47.02 | 41.45 | 0.922 |
|
| 49.12 | 47.84 | 46.53 | 42.12 | 40.66 | 39.93 | 39.10 | 38.24 | 37.87 | 36.34 | 4.563 |
|
| 48.13 | 47.57 | 47.04 | 44.62 | 42.39 | 42.08 | 40.54 | 39.42 | 38.30 | 37.27 | 10.347 |
|
| 40.20 | 40.04 | 39.12 | 38.89 | 37.12 | 35.43 | 34.75 | 34.13 | 31.57 | 30.58 | 1.8846 |
|
| 31.97 | 31.19 | 30.74 | 30.04 | 29.17 | 28.85 | 28.43 | 28.12 | 26.39 | 24.28 | 120.951 |
|
| 50.18 | 48.71 | 47.08 | 46.35 | 45.62 | 45.14 | 43.74 | 41.18 | 40.53 | 39.32 | 2.798 |
|
| 35.42 | 35.16 | 34.98 | 33.56 | 32.17 | 30.14 | 29.88 | 28.19 | 26.78 | 26.51 | 97.475 |
|
| 48.23 | 46.83 | 45.29 | 43.99 | 43.13 | 42.63 | 39.91 | 37.86 | 36.22 | 35.64 | 4.324 |
|
| 38.78 | 38.22 | 37.79 | 36.59 | 35.72 | 34.75 | 33.58 | 32.94 | 32.05 | 30.46 | 187.19 |
|
| 41.30 | 40.73 | 39.29 | 38.41 | 37.16 | 36.73 | 35.94 | 35.10 | 34.80 | 33.32 | 31.793 |
|
| 54.97 | 51.16 | 49.87 | 49.15 | 47.06 | 45.27 | 43.36 | 42.66 | 41.98 | 39.12 | 3.937 |
|
| 62.43 | 59.31 | 58.65 | 54.16 | 51.24 | 49.12 | 47.20 | 45.35 | 42.21 | 39.29 | 1.122 |
|
| 31.97 | 28.73 | 26.15 | 24.22 | 20.81 | 20.09 | 18.32 | 18.01 | 16.52 | 15.14 | 6.658 |
|
| 35.69 | 34.15 | 33.49 | 32.54 | 32.45 | 30.16 | 28.58 | 26.39 | 25.75 | 23.69 | 5.525 |
|
| 51.86 | 50.68 | 48.17 | 47.80 | 46.53 | 45.26 | 43.99 | 40.45 | 39.24 | 37.78 | 2.268 |
|
| 49.93 | 49.17 | 49.15 | 47.06 | 45.27 | 43.36 | 42.66 | 40.65 | 38.21 | 36.49 | 4.621 |
|
| 29.58 | 29.03 | 27.25 | 26.57 | 25.26 | 24.12 | 22.18 | 20.28 | 19.87 | 18.85 | 31.443 |
|
| 39.76 | 38.78 | 38.08 | 36.42 | 35.48 | 34.68 | 32.12 | 30.19 | 28.97 | 26.94 | 2.337 |
|
| 43.78 | 41.25 | 40.59 | 39.53 | 38.74 | 37.52 | 36.99 | 36.04 | 35.11 | 33.19 | 0.754 |
|
| 42.87 | 40.29 | 38.13 | 37.17 | 36.52 | 35.91 | 35.14 | 33.26 | 31.16 | 29.12 | 1.261 |
|
| 50.59 | 46.23 | 45.62 | 44.17 | 43.11 | 42.42 | 40.73 | 39.83 | 38.24 | 37.35 | 24.642 |
|
| 40.72 | 38.89 | 38.60 | 38.21 | 38.04 | 37.73 | 36.59 | 34.57 | 34.08 | 33.23 | 1.162 |
|
| 52.34 | 47.41 | 45.94 | 44.29 | 43.13 | 42.92 | 42.06 | 40.33 | 38.16 | 36.83 | 2.413 |
|
| 38.89 | 38.22 | 36.31 | 35.84 | 35.51 | 34.78 | 34.75 | 33.85 | 32.57 | 30.64 | 12.77 |
|
| 39.61 | 37.65 | 34.24 | 31.41 | 30.29 | 29.81 | 28.32 | 26.59 | 26.66 | 25.27 | 16.044 |
|
| 42.81 | 39.79 | 37.94 | 37.43 | 37.11 | 36.42 | 35.14 | 34.03 | 33.12 | 32.53 | 7.428 |
|
| 38.61 | 34.14 | 33.55 | 32.77 | 32.09 | 31.15 | 30.32 | 28.54 | 27.57 | 25.40 | 22.12 |
|
| 37.59 | 36.90 | 36.25 | 35.73 | 35.68 | 35.06 | 34.82 | 34.54 | 32.93 | 32.02 | 1.829 |
|
| 43.48 | 39.51 | 38.84 | 37.19 | 37.03 | 36.69 | 36.32 | 35.12 | 34.46 | 33.04 | 41.71 |
|
| 38.91 | 36.86 | 36.12 | 35.26 | 35.02 | 34.51 | 34.31 | 33.73 | 32.81 | 31.41 | 2.934 |
| ISL | 69.39 | 61.24 | 57.83 | 55.37 | 52.22 | 51.07 | 50.12 | 48.56 | 46.89 | 42.28 | 0.217 |
aCTC50 cytotoxicity concentration (μM) determined experimentally
Anticancer activity (% cytotoxicity) and CTC50 values of synthesized compounds on BT474 (breast cancer cell line)
| Treatment | % cytotoxicity (100 − % cell survival) of BT474 cell line at conc. (μM) | CTC50 (μM)a | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 100 | 33.33 | 11.11 | 3.7 | 1.23 | 0.41 | 0.13 | 0.045 | 0.015 | 0.005 | ||
| Log conc. | |||||||||||
| 2.00 | 1.52 | 1.05 | 0.57 | 0.09 | −0.39 | −0.89 | −1.35 | −1.82 | −2.30 | ||
|
| 28.73 | 28.11 | 27.45 | 26.28 | 25.92 | 25.37 | 24.64 | 23.12 | 22.64 | 20.06 | 61.336 |
|
| 26.66 | 23.31 | 22.19 | 20.47 | 19.85 | 18.14 | 17.99 | 17.37 | 16.56 | 16.18 | 5.496 |
|
| 41.35 | 40.32 | 39.37 | 38.82 | 37.56 | 36.26 | 35.55 | 34.19 | 32.11 | 30.65 | 8.743 |
|
| 32.09 | 30.34 | 29.44 | 28.10 | 27.13 | 26.82 | 26.23 | 25.34 | 24.24 | 23.19 | 1.746 |
|
| 40.37 | 38.91 | 37.21 | 36.96 | 35.73 | 33.14 | 32.29 | 31.76 | 31.02 | 30.89 | 2.798 |
|
| 59.31 | 55.26 | 52.38 | 50.12 | 48.54 | 45.32 | 43.76 | 41.28 | 39.05 | 37.60 | 1.561 |
|
| 38.22 | 37.84 | 36.21 | 35.19 | 34.87 | 34.15 | 33.18 | 32.07 | 31.45 | 30.59 | 2.346 |
|
| 32.69 | 32.09 | 31.26 | 30.89 | 30.38 | 29.83 | 28.61 | 27.96 | 27.18 | 26.01 | 11.147 |
|
| 31.97 | 30.32 | 29.34 | 28.72 | 28.14 | 27.13 | 26.25 | 25.78 | 25.06 | 24.32 | 3.656 |
|
| 39.44 | 38.21 | 37.91 | 37.09 | 36.69 | 35.37 | 34.95 | 34.13 | 33.27 | 33.11 | 11.552 |
|
| 33.85 | 33.29 | 32.92 | 32.11 | 31.02 | 30.56 | 29.44 | 28.93 | 27.72 | 26.34 | 127.620 |
|
| 37.27 | 34.77 | 32.45 | 31.08 | 30.13 | 29.38 | 28.67 | 28.11 | 28.01 | 27.14 | 2.418 |
|
| 50.81 | 45.31 | 42.19 | 40.62 | 37.19 | 35.84 | 33.41 | 32.15 | 30.07 | 29.13 | 1.007 |
|
| 46.38 | 44.19 | 42.44 | 39.51 | 38.20 | 37.56 | 34.12 | 33.86 | 32.75 | 30.46 | 1.028 |
|
| 46.32 | 43.67 | 41.82 | 40.72 | 39.54 | 38.21 | 37.77 | 36.69 | 34.95 | 34.13 | 9.215 |
|
| 36.61 | 35.52 | 34.59 | 33.33 | 32.16 | 31.36 | 30.24 | 29.47 | 28.13 | 27.42 | 1.884 |
|
| 27.87 | 26.43 | 25.71 | 24.22 | 22.81 | 20.98 | 20.13 | 19.76 | 19.43 | 18.80 | 10.336 |
|
| 38.89 | 37.95 | 36.07 | 35.68 | 34.42 | 33.11 | 31.92 | 30.64 | 29.31 | 28.53 | 1.195 |
|
| 51.16 | 50.38 | 49.11 | 48.46 | 47.56 | 47.13 | 46.28 | 45.39 | 44.21 | 43.90 | 2.349 |
|
| 64.14 | 60.28 | 58.64 | 56.72 | 54.23 | 52.17 | 50.09 | 47.21 | 45.80 | 42.38 | 0.751 |
|
| 40.06 | 38.46 | 37.71 | 34.74 | 33.24 | 32.73 | 31.29 | 29.98 | 28.39 | 27.27 | 1.473 |
|
| 65.97 | 41.46 | 40.56 | 40.2 | 38.97 | 38.05 | 37.05 | 36.38 | 35.84 | 35.26 | 13.723 |
|
| 64.99 | 62.26 | 60.68 | 56.34 | 50.12 | 46.10 | 42.01 | 41.47 | 39.42 | 38.81 | 2.414 |
|
| 67.11 | 58.80 | 54.83 | 53.61 | 50.42 | 47.02 | 44.37 | 42.60 | 41.45 | 38.13 | 0.794 |
|
| 39.40 | 38.00 | 37.37 | 36.80 | 36.75 | 34.22 | 33.96 | 33.52 | 33.42 | 33.28 | 11.557 |
|
| 56.21 | 47.52 | 41.77 | 37.86 | 31.92 | 29.89 | 28.93 | 27.27 | 26.43 | 25.17 | 12.770 |
|
| 38.66 | 38.22 | 36.12 | 35.80 | 35.51 | 34.78 | 34.75 | 33.86 | 32.57 | 30.64 | 112.202 |
|
| 38.14 | 36.17 | 34.74 | 33.23 | 32.82 | 31.42 | 29.23 | 28.71 | 28.02 | 27.38 | 18.345 |
|
| 47.67 | 41.55 | 38.42 | 35.17 | 34.21 | 33.76 | 32.92 | 30.64 | 29.11 | 29.02 | 1.281 |
|
| 41.29 | 40.50 | 39.19 | 37.56 | 36.73 | 36.12 | 35.42 | 34.59 | 33.31 | 31.52 | 6.324 |
|
| 61.43 | 56.93 | 52.13 | 49.34 | 45.14 | 43.57 | 40.13 | 37.35 | 34.64 | 30.38 | 1.361 |
| ISL | 73.52 | 66.14 | 62.46 | 54.71 | 52.94 | 50.79 | 49.03 | 46.42 | 44.97 | 42.23 | 0.348 |
aCTC50 cytotoxicity concentration (μM) determined experimentally
Anticancer activity (% cytotoxicity) and CTC50 values of synthesized compounds on NCI-H226 (lung cancer cell line)
| Treatment | % Cytotoxicity (100 − % cell survival) of NCI-H226 cell line at conc. (μM) | CTC50 (μM)a | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 100 | 33.33 | 11.11 | 3.7 | 1.23 | 0.41 | 0.13 | 0.045 | 0.015 | 0.005 | ||
| Log conc. | |||||||||||
| 2.00 | 1.52 | 1.05 | 0.57 | 0.09 | −0.39 | −0.89 | −1.35 | −1.82 | −2.30 | ||
|
| 27.86 | 27.49 | 27.09 | 26.55 | 26.13 | 25.46 | 24.94 | 24.22 | 23.14 | 22.41 | 145.347 |
|
| 39.46 | 37.21 | 36.30 | 35.96 | 35.11 | 34.69 | 34.05 | 33.46 | 32.87 | 32.12 | 33.268 |
|
| 54.16 | 51.24 | 49.12 | 47.20 | 45.35 | 42.21 | 39.29 | 38.91 | 38.19 | 37.65 | 2.527 |
|
| 42.56 | 42.06 | 39.73 | 38.26 | 38.02 | 37.34 | 36.29 | 35.23 | 35.11 | 34.16 | 17.482 |
|
| 34.59 | 33.33 | 32.16 | 31.26 | 30.59 | 29.89 | 29.55 | 28.93 | 28.11 | 27.31 | 7.965 |
|
| 52.87 | 50.14 | 48.31 | 46.52 | 45.78 | 42.90 | 41.57 | 39.72 | 38.63 | 37.24 | 1.197 |
|
| 41.75 | 41.35 | 40.29 | 39.37 | 38.14 | 37.84 | 37.13 | 36.95 | 36.10 | 35.77 | 22.274 |
|
| 40.92 | 38.89 | 38.22 | 36.05 | 35.61 | 33.65 | 32.94 | 32.17 | 31.57 | 30.46 | 52.953 |
|
| 49.15 | 47.06 | 45.27 | 43.36 | 42.66 | 41.98 | 39.12 | 38.44 | 37.26 | 36.29 | 1.119 |
|
| 38.98 | 38.32 | 36.52 | 35.08 | 34.91 | 34.79 | 34.15 | 33.59 | 32.75 | 30.41 | 12.829 |
|
| 49.15 | 47.26 | 45.31 | 43.41 | 41.96 | 41.18 | 39.12 | 37.05 | 36.38 | 35.51 | 1.816 |
|
| 54.52 | 51.14 | 50.83 | 49.22 | 48.64 | 47.65 | 45.39 | 42.38 | 41.25 | 38.76 | 1.018 |
|
| 65.97 | 59.62 | 57.09 | 55.18 | 54.64 | 51.26 | 48.28 | 46.54 | 44.85 | 41.28 | 0.978 |
|
| 46.01 | 43.19 | 42.63 | 41.32 | 40.65 | 39.82 | 37.34 | 36.75 | 34.95 | 33.52 | 3.108 |
|
| 36.94 | 36.21 | 35.13 | 34.55 | 32.17 | 30.41 | 29.35 | 29.17 | 28.36 | 27.44 | 10.735 |
|
| 42.44 | 41.12 | 40.65 | 39.07 | 38.79 | 37.41 | 37.05 | 35.48 | 33.62 | 33.48 | 13.829 |
|
| 40.27 | 38.88 | 38.60 | 38.21 | 38.04 | 37.79 | 36.59 | 34.75 | 34.03 | 33.23 | 1.164 |
|
| 38.92 | 38.50 | 37.91 | 35.98 | 35.37 | 35.66 | 35.17 | 34.59 | 34.13 | 33.72 | 6.342 |
|
| 36.05 | 35.80 | 35.53 | 34.87 | 34.52 | 33.48 | 31.75 | 30.46 | 29.97 | 29.04 | 12.729 |
|
| 67.99 | 65.83 | 60.68 | 56.43 | 52.12 | 46.10 | 42.62 | 40.07 | 39.26 | 38.76 | 1.784 |
|
| 38.99 | 38.74 | 37.12 | 36.26 | 36.11 | 35.72 | 35.32 | 33.62 | 32.79 | 30.66 | 10.215 |
|
| 42.36 | 41.13 | 39.07 | 38.10 | 37.89 | 37.01 | 36.15 | 35.32 | 34.84 | 33.29 | 5.674 |
|
| 37.99 | 37.72 | 37.02 | 36.62 | 36.47 | 36.11 | 35.72 | 35.43 | 29.46 | 27.75 | 1.487 |
|
| 43.51 | 40.34 | 38.19 | 37.73 | 36.15 | 35.87 | 35.12 | 34.15 | 33.25 | 31.49 | 5.726 |
|
| 53.02 | 48.22 | 47.78 | 43.14 | 41.21 | 40.59 | 38.31 | 37.46 | 36.27 | 35.65 | 2.268 |
|
| 51.36 | 49.32 | 48.22 | 47.61 | 45.79 | 43.35 | 42.54 | 41.86 | 40.27 | 39.11 | 12.763 |
|
| 40.39 | 38.72 | 37.14 | 36.91 | 35.67 | 34.95 | 33.42 | 32.39 | 31.24 | 30.26 | 17.327 |
|
| 42.47 | 39.75 | 39.20 | 38.61 | 37.51 | 36.33 | 35.06 | 34.11 | 33.17 | 32.72 | 166.376 |
|
| 39.98 | 39.25 | 37.94 | 37.46 | 37.24 | 36.39 | 36.32 | 35.35 | 35.01 | 32.85 | 1.467 |
|
| 38.66 | 38.57 | 36.72 | 35.27 | 34.95 | 34.59 | 34.14 | 33.97 | 33.92 | 33.61 | 9.215 |
|
| 52.43 | 45.35 | 42.72 | 39.13 | 37.04 | 36.06 | 35.27 | 34.62 | 33.23 | 32.98 | 0.913 |
| ISL | 59.26 | 44.69 | 38.58 | 36.46 | 34.12 | 32.98 | 31.11 | 30.20 | 28.42 | 26.37 | 0.313 |
aCTC50 cytotoxicity concentration (μM) determined experimentally